MedTrace Logo

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

NCT06412471 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 235

Last updated 2024-07-30

No results posted yet for this study

Summary

This study includes two parts, part A is for non-squamous NSCLC and part B is for squamous NSCLC.

Conditions

  • First-line Advanced NSCLC Patients

Interventions

DRUG

SSGJ-707

bispecific antibody

DRUG

carboplatin

chemotherapy

DRUG

Pemetrexed

chemotherapy

DRUG

paclitaxel

chemotherapy

DRUG

PD-1/L1

Immune checkpoint inhibitors

DRUG

Paclitaxel-albumin

chemotherapy

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-26
Primary Completion
2025-07-31
Completion
2025-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06412471 on ClinicalTrials.gov